Defensoria pública: uma forma de promoção do acesso à justiça em Santa Catarina

This article seeks, firstly, to present access to justice as a way to ensure that everyone can resolve their demands in a judicial or extrajudicial manner. Then, it seeks to address the importance of the Public Defender's Office, especially the State of Santa Catarina, demonstrating its importance since its creation, to the main challenges for the effective access to justice. The aim is also to present the obstacles of the Santa Catarina Public Defender's Office in implementing and guaranteeing access to justice for all citizens, as well as showing that, despite all the challenges, the Public Defender's Office of the State of Santa Catarina is the main institution to carry out the Principle of Human Dignity, especially for vulnerable people. Thus, even if the number of civil servants is low, and the institution is not present in all counties, the Public Defender's Office is one of the best state institutions to guarantee access to justice for vulnerable people. Thus, it is concluded that the Public Defender of the State of Santa Catarina is the institution that guarantees access to justice in the state, even with a large demand, low staff and not being present in all districts of the state. Thus, the method of deductive approach was adopted, since it assumes that the Public Defender of Santa Catarina meets the principle of access to justice, while the research technique will be based on research on jurisprudence and doctrines.O presente artigo busca primeiramente, apresentar o acesso à Justiça como forma de garantir que todos possam resolver suas demandas de forma judicial ou extrajudicial. Em seguida, busca-se tratar sobre a importância da Defensoria Pública, em especial a do Estado de Santa Catarina, demonstrando a sua importância desde a sua criação, até os principais desafios para a efetivação do acesso à Justiça. Busca-se também, apresentar os entraves da Defensoria Pública catarinense em efetivar e garantir o acesso à Justiça a todos os cidadãos, bem como evidenciar que, apesar de todos os desafios, a Defensoria Pública do Estado de Santa Catarina é a principal instituição para efetivar o Princípio da Dignidade da Pessoa Humana, em especial para as pessoas vulneráveis. Desta forma, mesmo que o efetivo de servidores seja baixo, e que a instituição não esteja presente em todas as comarcas, a Defensoria Pública é uma das melhores instituições estatais para garantir o acesso à Justiça para as pessoas vulneráveis. Conclui-se, assim, que a Defensoria Pública do Estado de Santa Catarina é a instituição garantidora do acesso à Justiça no estado, mesmo com uma grande demanda, baixo efetivo e não estando presente em todas as comarcas do estado. Sendo assim, adotou-se o método de abordagem dedutivo, visto que parte do pressuposto que a Defensoria Pública de Santa Catarina atende o princípio do acesso à Justiça, enquanto que a técnica de pesquisa será baseada em pesquisas de jurisprudências e doutrinas

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Molecular differentiation of Angiostrongylus costaricensis, A. cantonensis, and A. vasorum by polymerase chain reaction- restriction fragment length polymorphism

Angiostrongylus cantonensis, A. costaricensis, and A. vasorum are etiologic agents of human parasitic diseases. Their identification, at present, is only possible by examining the adult worm after a 40-day period following infection of vertebrate hosts with the third-stage larvae. In order to obtain a diagnostic tool to differentiate larvae and adult worm from the three referred species, polymerase chain reaction-restriction fragment length polymorphism was carried out. The rDNA second internal transcribed spacer (ITS2) and mtDNA cytochrome oxidase I regions were amplified, followed by digestion of fragments with the restriction enzymes RsaI, HapII, AluI, HaeIII, DdeI and ClaI. The enzymes RsaI and ClaI exhibited the most discriminating profiles for the differentiation of the regions COI of mtDNA and ITS2 of rDNA respectively. The methodology using such regions proved to be efficient for the specific differentiation of the three species of Angiostrongylus under study

Molecular differentiation of Angiostrongylus costaricensis, A. cantonensis, and A. vasorum by polymerase chain reaction- restriction fragment length polymorphism

Angiostrongylus cantonensis, A. costaricensis, and A. vasorum are etiologic agents of human parasitic diseases. Their identification, at present, is only possible by examining the adult worm after a 40-day period following infection of vertebrate hosts with the third-stage larvae. In order to obtain a diagnostic tool to differentiate larvae and adult worm from the three referred species, polymerase chain reaction-restriction fragment length polymorphism was carried out. The rDNA second internal transcribed spacer (ITS2) and mtDNA cytochrome oxidase I regions were amplified, followed by digestion of fragments with the restriction enzymes RsaI, HapII, AluI, HaeIII, DdeI and ClaI. The enzymes RsaI and ClaI exhibited the most discriminating profiles for the differentiation of the regions COI of mtDNA and ITS2 of rDNA respectively. The methodology using such regions proved to be efficient for the specific differentiation of the three species of Angiostrongylus under study